Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cirrhosis: early-phase trial registry
29 of 54 indexed Cirrhosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #261 of 28,707 conditions by registered trial count.
54 US clinical trials · 29 currently recruiting · #261 of 28,707 conditions by registered trial count
Cirrhosis: 54 US clinical trials tracked, 29 recruiting.
Cirrhosis is the subject of 54 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 5 of these trials.
Enrollment posture brief
Registry condition cirrhosis
OPEN 29 | RECR 54% | LATE 7 | EARLY 20 | RANK #261 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Uterine Cancer (54% recruiting · 28 trials)
Cirrhosis lists 29 open slots (54% of 54 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cirrhosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cirrhosis is recruiting above its size-band peers.
29 of 54 indexed trials (53.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cirrhosis trials is spread across many organizations.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 5 of 54 trials (9.3%). 37 distinct sponsors appear on at least one study for this condition label.
-
Most Cirrhosis trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 54 trials that report a genuine target (sentinel values excluded). 35 of those (64.8%) plan for fewer than 100 participants.
-
Cirrhosis research is mostly interventional.
41 interventional and 13 observational studies make up this index (75.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
54 total, page 1 of 2
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
VA Office of Research and Development
NCT05486572
CirrhosisRx CDS System
University of California, San Francisco
NCT05967273
Blood Collection Biorepository for Liver Disease Research
State University of New York at Buffalo
NCT03025074
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Can-Fite BioPharma
NCT05201404
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
University of Pennsylvania
NCT05260268
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05832229
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Massachusetts General Hospital
NCT05998330
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Vir Biotechnology
NCT05484206
Oral Health In Cirrhosis of the Liver (ORACLE)
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT06052150
Adverse Outcomes and Mortality in Liver Transplant
Mayo Clinic
NCT05477277
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
Virginia Commonwealth University
NCT05548452
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Giuseppe Cullaro, MD
NCT06937307
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Raymond Chung
NCT05028829
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
CAMC Health System
NCT06764966
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
The Cleveland Clinic
NCT03121404
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Zydus Therapeutics
NCT05045482
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT06052176
Copper Supplementation in Cirrhosis
University of Washington
NCT07471542
Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
Mayo Clinic
NCT06306963
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
Massachusetts General Hospital
NCT05205954
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT06464952
Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis
University of Michigan
NCT06932783
Empagliflozin in Patients With Cirrhosis and Ascites
Yale University
NCT05726032
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Anahita Rabiee MD MHS
NCT06812390
Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis
The Cleveland Clinic
NCT03225677
Affect of Melatonin on Sleep and Cognition in Cirrhosis
Weill Medical College of Cornell University
NCT07046429
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Inova Health Care Services
NCT06007846
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
Mayo Clinic
NCT06425380
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
Massachusetts General Hospital
NCT07417163
The Impact of Liver Cirrhosis on Outcomes in Trauma Patients
Methodist Health System
NCT05170854
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
NCT05064553
Extracellular RNA Markers of Liver Disease and Cancer
Mayo Clinic
NCT02908048
Liver Cirrhosis Network Cohort Study
Northwestern University
NCT05740358
Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
VA Office of Research and Development
NCT03654053
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
NCT02968810
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
NCT02626312
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Davendra Sohal
NCT05027425
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis
National Cancer Institute (NCI)
NCT03278925
Prevention of Recurrent Hepatitis B After Liver Transplantation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00059267
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
Bausch Health Americas
NCT01842581
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Amgen
NCT00999167
Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
Virginia Commonwealth University
NCT01157845
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis
University of Virginia
NCT04642391
FMT in Cirrhosis and Hepatic Encephalopathy
VA Office of Research and Development
NCT03796598
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
Ocelot Bio
NCT05309200
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01888900
Effect of Yogurt on Minimal Hepatic Encephalopathy
Medical College of Wisconsin
NCT00312078
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
Sequana Medical N.V.
NCT02400164
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02400216
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
US Department of Veterans Affairs
NCT00108355
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 13 |
| Phase 3 | 4 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Cirrhosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cirrhosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cirrhosis page
54 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Cirrhosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors the most Cirrhosis trials on record, review their full trial history before evaluating a specific study. See National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cirrhosis condition card totals 54 registered trials; most-linked intervention Placebo; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.